Prazosin - PharmaKB

Prazosin

Minipress, Minizide, Prazosin (prazosin) is a small molecule pharmaceutical. Prazosin was first approved as Minizide on 1982-01-01. It is used to treat hypertension, prostatic hyperplasia, raynaud disease, and urinary retention in the USA. The pharmaceutical is active against alpha-1A adrenergic receptor, alpha-1B adrenergic receptor, and alpha-1D adrenergic receptor. In addition, it is known to target alpha-2B adrenergic receptor, alpha-2A adrenergic receptor, and alpha-2C adrenergic receptor.

Download report

Favorite

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

Therapeutic Areas

Therapeutic Area	MeSH
urogenital diseases	D000091642
cardiovascular diseases	D002318
skin and connective tissue diseases	D017437

Trade Name

FDA

EMA

Minipress, Prazosin (discontinued: Minipress, Prazosin)

Drug Products

FDA

EMA

New Drug Application (NDA)

Abbreviated New Drug Application (ANDA)

Prazosin hydrochloride

Tradename	Company	Number	Date	Products
MINIPRESS	Pfizer	N-017442 RX	1982-01-01	3 products, RLD, RS

Show 1 discontinued

Polythiazide

Prazosin hydrochloride

Tradename	Company	Number	Date	Products
MINIZIDE	Pfizer	N-017986 DISCN	1982-01-01	3 products

Hide discontinued

Labels

FDA

EMA

Brand Name	Status	Last Update
prazosin	ANDA	2023-09-15
prazosin hcl	ANDA	2025-01-22
prazosin hydrochloride	ANDA	2025-10-01

Indications

FDA

EMA

Indication	Ontology	MeSH	ICD-10
hypertension	EFO_0000537	D006973	I10
urinary retention	—	D016055	R33
prostatic hyperplasia	EFO_0000284	D011470	N40
raynaud disease	EFO_1001145	D011928	I73.0
heart failure	EFO_0003144	D006333	I50
glomerulonephritis	—	D005921	N05
liver cirrhosis	EFO_0001422	D008103	K74.0
nephrotic syndrome	EFO_0004255	D009404	N04
edema	—	D004487	R60.9

Agency Specific

FDA

EMA

No data

Patent Expiration

No data

ATC Codes

C: Cardiovascular system drugs

— C02: Antihypertensives

— C02C: Antiadrenergic agents, peripherally acting

— C02CA: Alpha-adrenoreceptor antagonists, peripherally acting

— C02CA01: Prazosin

— C02L: Antihypertensives and diuretics in combination

— C02LE: Alpha-adrenoreceptor antagonists and diuretics

— C02LE01: Prazosin and diuretics

HCPCS

No data

Clinical

Clinical Trials

124 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

No data

Indications Phases 3

No data

Indications Phases 2

No data

Indications Phases 1

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Hypertension	D006973	EFO_0000537	I10	1	—	—	—	—	1

Indications Without Phase

No data

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	Prazosin
INN	prazosin
Description	Prazosin is a member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively. It has a role as an antihypertensive agent, an alpha-adrenergic antagonist and an EC 3.4.21.26 (prolyl oligopeptidase) inhibitor. It is a member of piperazines, a member of quinazolines, a member of furans, a monocarboxylic acid amide and an aromatic ether.
Classification	Small molecule
Drug class	antihypertensives (prazosin type)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	COc1cc2nc(N3CCN(C(=O)c4ccco4)CC3)nc(N)c2cc1OC

Identifiers

PDB	—
CAS-ID	19216-56-9
RxCUI	—
ChEMBL ID	CHEMBL2
ChEBI ID	8364
PubChem CID	4893
DrugBank	DB00457
UNII ID	XM03YJ541D (ChemIDplus, GSRS)

Target

Agency Approved

ADRA1D

Organism

Homo sapiens

Gene name

ADRA1D

Gene synonyms

ADRA1A

NCBI Gene ID

146

Protein name

alpha-1D adrenergic receptor

Protein synonyms

adrenergic, alpha -1D-, receptor, adrenergic, alpha-1A-, receptor, Alpha-1A adrenergic receptor, Alpha-1D adrenoceptor, Alpha-1D adrenoreceptor, Alpha-adrenergic receptor 1a

Uniprot ID

Q9NPY0

Mouse ortholog

Adra1d (11550)

alpha-1D adrenergic receptor (P97714)

Alternate

NQO2

Organism

Homo sapiens

Gene name

NQO2

Gene synonyms

NMOR2

NCBI Gene ID

4835

Protein name

ribosyldihydronicotinamide dehydrogenase [quinone]

Protein synonyms

N-ribosyldihydronicotinamide:quinone reductase 2, NAD(P)H dehydrogenase, quinone 2, NAD(P)H menadione oxidoreductase-1, dioxin-inducible-2, NAD(P)H quinone dehydrogenase 2, NRH dehydrogenase [quinone] 2, NRH:quinone oxidoreductase 2, QR2, Quinone reductase 2, ribosyldihydronicotinamide dehydrogenase

Uniprot ID

Q5TD04

Mouse ortholog

Nqo2 (18105)

ribosyldihydronicotinamide dehydrogenase [quinone] (Q9JI75)

Variants

No data

Financial

Revenue by drug

€

₣

No data

Estimated US medical usage

Prazosin

Polythiazide

Total medical expenditures per year (USD, in millions)

Mock data
Subscribe for the real data

Number of persons purchased

Mock data
Subscribe for the real data

Number of purchases

Mock data
Subscribe for the real data

Refill frequency

Mock data
Subscribe for the real data

Price per prescription (USD)

Mock data
Subscribe for the real data

Prazosin

Total medical expenditures per year (USD, in millions)

Mock data
Subscribe for the real data

Number of persons purchased

Mock data
Subscribe for the real data

Number of purchases

Mock data
Subscribe for the real data

Refill frequency

Mock data
Subscribe for the real data

Price per prescription (USD)

Mock data
Subscribe for the real data

Tabular view

Trends

PubMed Central

Top Terms for Disease or Syndrome:

Mock data
Subscribe for the real data

Additional graphs summarizing 10,069 documents

View more details

Safety

Black-box Warning

No Black-box warning

Adverse Events

Top Adverse Reactions

Mock data
Subscribe for the real data

1,858 adverse events reported

View more details